Telix Pharmaceuticals (TLX) Current Deferred Revenue (2023 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Current Deferred Revenue of $402000.0 for Q4 2025, down 94.53% year-over-year from $7.4 million in Q4 2024, and down 94.53% quarter-over-quarter from $7.4 million in Q4 2024.
Telix Pharmaceuticals (TLX) Current Deferred Revenue (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Current Deferred Revenue for 3 consecutive years, with $402000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Deferred Revenue fell 94.53% year-over-year to $402000.0; the TTM figure through Dec 2025 stood at $402000.0 (down 94.53% YoY), while the FY2025 annual figure was $402000.0, down 94.23% from the prior year.
- Current Deferred Revenue retreated to $402000.0 in Q4 2025 per TLX's latest filing, from $7.4 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $7.4 million in Q4 2024 and bottomed at $402000.0 in Q4 2025.
- Historically, Current Deferred Revenue has averaged $5.0 million across 3 years, with a median of $7.2 million in 2023.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue gained 2.77% — and 2025, when it plunged 94.53%.
- Telix Pharmaceuticals' Current Deferred Revenue stood at $7.2 million in 2023, then climbed by 2.77% to $7.4 million in 2024, then slumped by 94.53% to $402000.0 in 2025.
- Business Quant data shows TLX's Current Deferred Revenue at $402000.0 in Q4 2025, $7.4 million in Q4 2024, and $7.2 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Telix Pharmaceuticals | 4.00 Bn | 3.86 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 402,000.00 |
| Dec 31, 2024 | 7.36 Mn |
| Dec 31, 2023 | 7.16 Mn |